-
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted...
IN THE SPOTLIGHT
-
Initial Treatment Options for HER2+ NSCLC Expand with New Zongertinib Approval
On February 26, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) as an initial treatment option for newly diagnosed... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Accelerated Approval for HER2-positive NSCLC
On November 19, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sevabertinib (Hyrnuo®) to treat patients with locally-advanced or metastatic... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000...
Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
无驱动基因 IV 期 NSCLC ASCO 指南更新！仅 1 个药物新增推荐_腾讯新闻
Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy
Editorial: Advancing NSCLC treatment: overcoming challenges in immune checkpoint inhibitor therapy
Editorial: Treatment response and resistance to targeted therapies for NSCLC
Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study
Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study
The Possible Relationship Between Adverse Drug Reactions and Potential Drug–Drug Interactions in Patients with NSCLC Treated with EGFR Inhibitors
The Possible Relationship Between Adverse Drug Reactions and Potential Drug–Drug Interactions in Patients with NSCLC Treated with EGFR Inhibitors
A Mechanistic Pharmacokinetic/Pharmacodynamic Model for Sequence-Dependent Synergy in Pemetrexed–Osimertinib Combinations Against Non-Small Cell Lung Cancer (NSCLC): Translational Insights
A Mechanistic Pharmacokinetic/Pharmacodynamic Model for Sequence-Dependent Synergy in Pemetrexed–Osimertinib Combinations Against Non-Small Cell Lung Cancer (NSCLC): Translational Insights